Welcome to our dedicated page for Abcam Plc news (Ticker: ABCM), a resource for investors and traders seeking the latest updates and insights on Abcam Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abcam Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abcam Plc's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
The Global Polyclonal Antibodies Market is projected to grow at a CAGR of 4% from 2022 to 2028, driven by increasing chronic diseases, healthcare expenditure, and technological advancements. The market benefits from a rise in the demand for personalized medicine, particularly in the Middle East and Africa.
Key players include Thermo Fisher Scientific, Merck KGaA, and Abcam (ABCZF). The competitive landscape is intense, with significant challenges including ethical concerns about animal sourcing and high production costs.
Opportunities arise from the growing application of polyclonal antibodies in diagnostics, especially for early disease detection. Key trends influencing market dynamics include the rising prevalence of chronic diseases and the increasing awareness of antibody benefits.
Abcam plc, a leading global supplier of life science research tools, has announced upcoming investor events. Michael Baldock, the Chief Financial Officer, will present at two conferences: the Bank of America 2023 Health Care Conference on May 9, 2023, and William Blair's 43rd Annual Growth Stock Conference on June 6, 2023. These events are significant for investors and will be accessible via a live audio webcast on Abcam's corporate website. Abcam aims to enhance the life sciences sector by providing validated antibodies, assays, and research tools. The company supports approximately 750,000 researchers across over 130 countries, continuously improving its offerings based on customer feedback. Founded in 1998 and headquartered in Cambridge, UK, Abcam's American Depositary Shares are traded on Nasdaq under the symbol ABCM.
Abcam plc, a leader in life science research tools, announced upcoming investor events to enhance communication with stakeholders. Chief Financial Officer Michael Baldock will present at the Bank of America 2023 Health Care Conference on May 9, 2023, at 10:40 AM PDT and at William Blair's 43rd Annual Growth Stock Conference on June 6, 2023, at 12:40 PM CDT. A live audio webcast of these presentations will be available on Abcam's investor website. Abcam, founded in 1998 and headquartered in Cambridge, UK, serves approximately 750,000 life science researchers globally, providing validated antibodies, assays, and other tools to support research and clinical goals, thereby advancing biology understanding and health improvements.
Abcam plc (NASDAQ: ABCM) released a preliminary trading update for the quarter ending March 31, 2023, reporting estimated revenue surpassing £100 million and an adjusted operating profit exceeding 25%. The company highlighted double-digit revenue growth in the Americas and EMEA, with China showing a return to high-single digit growth year-over-year. Abcam anticipates approximately 45% of its 2023 revenue will occur in the first half of the year, maintaining in-line with Board expectations. The full-year revenue guidance is reiterated at £420 million to £440 million, reflecting a 15% to 20% growth. For FY2024, Abcam aims for revenue between £450 million to £525 million with adjusted operating profit margins above 30%. The trading update is based on unaudited management accounts and should not be relied upon by other parties.
Lunaphore announced a collaboration with abcam to co-market primary antibodies specifically validated for the COMET™ platform. This partnership allows researchers to use abcam's antibodies without conjugation, enhancing scalability and reproducibility in assays. The agreement aims to address the reproducibility crisis in life sciences through trusted tools for multiplex immunofluorescence analysis. Lunaphore's COMET™ platform is a high-throughput solution enabling automated multiplex analysis, facilitating various research applications. The two companies will present data at the upcoming AACR Annual Meeting 2023, showcasing advancements in single-cell analysis of tumor stroma.
Abcam plc (Nasdaq: ABCM) announced the publication of its 2022 Annual Report and Accounts, following the release of its final results for the year ended December 31, 2022, on March 20, 2023. The documents are accessible through Abcam's website, and hard copies will be sent to shareholders who opted for paper communications. The Annual General Meeting notice is included in this publication. Abcam, a leader in life science research tools, aims to support researchers globally with highly validated antibodies and assays, enhancing confidence in their results. Founded in 1998 and headquartered in Cambridge, UK, Abcam serves approximately 750,000 researchers in over 130 countries.
